These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 15536464)

  • 1. Postmarketing surveillance for drug safety.
    Holden WL; Scarazzini LJ
    Clin Pharmacol Ther; 2004 Nov; 76(5):503; author reply 504-5. PubMed ID: 15536464
    [No Abstract]   [Full Text] [Related]  

  • 2. Improving the Food and Drug Administration's mandate to ensure postmarketing drug safety.
    Qato DM; Alexander GC
    JAMA; 2011 Oct; 306(14):1595-6. PubMed ID: 21990303
    [No Abstract]   [Full Text] [Related]  

  • 3. Raising the safety bar--the FDA's coxib meeting.
    Okie S
    N Engl J Med; 2005 Mar; 352(13):1283-5. PubMed ID: 15800221
    [No Abstract]   [Full Text] [Related]  

  • 4. Adverse drug reaction processing in the United States and its dependence on physician reporting: zomepirac (Zomax) as a case in point.
    Corre KA; Spielberg TE
    Ann Emerg Med; 1988 Feb; 17(2):145-9. PubMed ID: 3257365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mandatory pharmacovigilance.
    Maksymowych WP
    CMAJ; 2003 Mar; 168(6):672; discussion 672-3. PubMed ID: 12642413
    [No Abstract]   [Full Text] [Related]  

  • 6. COX-2 inhibitors and the heart: putting risk in perspective.
    Bobadilla RV; Barnett EM; Randels CL
    Adv Nurse Pract; 2005 Nov; 13(11):48-50. PubMed ID: 16295003
    [No Abstract]   [Full Text] [Related]  

  • 7. Drug review and postmarketing surveillance programs are sound, but systems approach to risk management is needed, says FDA.
    Miller JL
    Am J Health Syst Pharm; 1999 Jul; 56(13):1294,6. PubMed ID: 10683122
    [No Abstract]   [Full Text] [Related]  

  • 8. IOM advises FDA on ethics in postmarket safety trials.
    Kuehn BM
    JAMA; 2010 Aug; 304(6):627. PubMed ID: 20699450
    [No Abstract]   [Full Text] [Related]  

  • 9. Drug safety on trial. Last year's withdrawal of the anti-arthritis drug Vioxx triggered a debate about how to better monitor drug safety even after approval.
    Greener M
    EMBO Rep; 2005 Mar; 6(3):202-4. PubMed ID: 15741969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FDA Adds Online REMS Table.
    Aschenbrenner DS
    Am J Nurs; 2017 Nov; 117(11):21. PubMed ID: 29076851
    [No Abstract]   [Full Text] [Related]  

  • 11. Ethical considerations in studying drug safety--the Institute of Medicine report.
    Mello MM; Goodman SN; Faden RR
    N Engl J Med; 2012 Sep; 367(10):959-64. PubMed ID: 22913661
    [No Abstract]   [Full Text] [Related]  

  • 12. Analysis and recommendations for agency action regarding nonsteroidal antiinflammatory drugs and cardiovascular risk.
    U.S. Food and Drug Administration
    J Pain Palliat Care Pharmacother; 2005; 19(4):83-97. PubMed ID: 16431839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FDA's drug safety initiative: resolutions or more questions? Regulators defend past actions, future plans.
    Young D
    Am J Health Syst Pharm; 2005 Jul; 62(13):1333-4, 1336. PubMed ID: 15972367
    [No Abstract]   [Full Text] [Related]  

  • 14. [Peripheral neuropathy and leflunomide].
    Santiago T; Rovisco J; Silva J; Malcata A
    Acta Reumatol Port; 2011; 36(3):313-4. PubMed ID: 22113609
    [No Abstract]   [Full Text] [Related]  

  • 15. Evaluating drug effects in the post-Vioxx world: there must be a better way.
    Avorn J
    Circulation; 2006 May; 113(18):2173-6. PubMed ID: 16684873
    [No Abstract]   [Full Text] [Related]  

  • 16. A primer of drug safety surveillance: an industry perspective. Part II: Product labeling and product knowledge.
    Allan MC
    J Pharm Technol; 1992; 8(5):198-202. PubMed ID: 10171208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How to avoid another 'Vioxx'.
    Frantz S
    Nat Rev Drug Discov; 2005 Jan; 4(1):5-7. PubMed ID: 15690595
    [No Abstract]   [Full Text] [Related]  

  • 18. Legal perspectives in causality assessment.
    Freilich WB
    Drug Inf J; 1984; 18(3-4):211-7. PubMed ID: 10268552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FDA officials argue over safety of new arthritis drug.
    Moynihan R
    BMJ; 2003 Mar; 326(7389):565. PubMed ID: 12637379
    [No Abstract]   [Full Text] [Related]  

  • 20. Assessing Drug Safety in Children - The Role of Real-World Data.
    McMahon AW; Dal Pan G
    N Engl J Med; 2018 Jun; 378(23):2155-2157. PubMed ID: 29874532
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.